Privium Fund Management’s Lexeo Therapeutics LXEO Stock Holding History

Privium Fund Management’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$524K	Hold	155,000	–	–	0.1%	47
2026 Q2	$722K	Sell	155,000 -50,000	-24%	-$270K	0.13%	50
2026 Q1	$1.18M	Buy	205,000 +12,450	+6%	+$88.2K	0.25%	41
2025 Q4	$1.91M	Buy	192,550 +194	+0.1%	+$1.77K	0.35%	33
2025 Q3	$1.28M	Buy	192,356 +14,000	+8%	+$67.7K	0.23%	38
2025 Q2	$753K	Buy	178,356 +18,158	+11%	+$59.7K	0.16%	39
2025 Q1	$556K	Buy	160,198 +22,083	+16%	+$97.8K	0.14%	40
2024 Q4	$909K	Buy	+138,115	New	+$1.09M	0.21%	35

Other funds holding LXEO

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Privium Fund Management's LXEO Position: Q3 2026 in Review

Privium Fund Management held its Lexeo Therapeutics (LXEO) position steady in Q3 2026 at 155,000 shares worth $524K. The position accounts for 0.1% of the portfolio, ranked #47.

Privium Fund Management first reported a position in LXEO in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.91M in Q4 2025. 60 funds tracked by Wall St. Rank hold LXEO as of Q3 2026.

Privium Fund Management held 155,000 shares of Lexeo Therapeutics worth $524K as of Q3 2026.
Privium Fund Management left its Lexeo Therapeutics share count unchanged in Q3 2026.
Lexeo Therapeutics made up 0.1% of Privium Fund Management's portfolio in Q3 2026, its #47 holding.
Privium Fund Management first reported a position in Lexeo Therapeutics in Q4 2024 and has held it in 8 quarters since.
Privium Fund Management's Lexeo Therapeutics position peaked at $1.91M in Q4 2025.
60 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2026.

Based on Privium Fund Management's 13F filing for Q3 2026, filed 3 Nov 2026.